Marine Compound Discovery Shows Promise of Improved Drug Treatment for COPD Patients

Published Online: Thursday, January 16, 2014
Follow Pharmacy_Times:
University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.

Related Articles
Notable outbreaks over the past 2 decades have qualified enterovirus D68 as an emerging pathogen.
Offering advice on healthy eating and exercise to overweight or obese pregnant women can improve birth outcomes.
The FDA today approved pirfenidone (Esbriet) and nintedanib (Ofev) for the treatment of idiopathic pulmonary fibrosis.
The disease burden of smoking remains immense despite widespread tobacco cessation efforts.
Latest Issues
$auto_registration$